Nirsevimab

• UNSPSC Description:

  Nirsevimab (MEDI8897) is a recombinant monoclonal antibody against human respiratory syncytial virus (RSV). Nirsevimab has neutralizing activity against RSV A and RSV B viruses, with IC50 values of 5.42 ng/mL and 9.71 ng/mL, respectively. Nirsevimab can be used for research on respiratory infections[1][2].

• Target Antigen:

  RSV

• Type:

  Inhibitory Antibodies

• Related Pathways:

  Anti-infection

• Applications:

  COVID-19-anti-virus

• Field of Research:

  Infection

• Assay Protocol:

  https://www.medchemexpress.com/nirsevimab.html

• Purity:

  98.00

• Solubility:

  10 mM in DMSO

• Smiles:

  [Nirsevimab]

• References & Citations:

  [1]Brady T, et al. Fc-mediated functions of nirsevimab complement direct respiratory syncytial virus neutralization but are not required for optimal prophylactic protection. Front Immunol. 2023 Oct 11;14:1283120.|[2]Ma J, et. Exacerbated lung inflammation in offspring with high maternal antibody levels following secondary RSV exposure. Front Immunol. 2024 Apr 30;15:1377374.

• Shipping Conditions:

  Dry Ice

• Storage Conditions:

  Store at -80°C for 2 years

• Clinical Information:

  Launched

• CAS Number:

  1989556-22-0